Sophia Genetics SA cash flow statement

In fiscal 2025, Sophia Genetics SA's operations generated −$35.9m of cash; it spent $574,000 on capital projects, leaving free cash flow of −$36.5m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Sophia Genetics SA: cash flow statement, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	−32	−32	−58	−70	−53	−45	−36
Depreciation and amortisation	2	2	4	6	8	9	10
Stock-based pay	1	1	9	14	15	16	16
Capital spending	1	0	3	4	1	0	1
Free cash flow	−33	−32	−61	−74	−55	−45	−36
Free cash flow after stock pay	−34	−34	−69	−88	−70	−61	−53

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: OPRX vs SOPH CCLD vs SOPH AMWL vs SOPH HCTI vs SOPH

More: Health Care Technology stocks compared, Health Care sector, rankings of US companies

Figures from Sophia Genetics SA's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Sophia Genetics SA.